“`html
FRANKLIN LAKES, N.J., Oct. 8, 2025 – BD (Becton, Dickinson and Company) (NYSE: BDX), a global medical technology giant, is teaming up with Opentrons Labworks, Inc., a leader in lab automation renowned for its expansive deployment of over 10,000 robotic systems. The multi-year collaboration aims to revolutionize single-cell multiomics research by integrating Opentrons’ robotic liquid-handling technology into BD’s instrumentation. The move promises to dramatically accelerate and scale disease research and drug development.
The partnership strategically addresses a bottleneck in the rapidly evolving field of single-cell multiomics. By automating critical experimental steps, researchers can overcome limitations in throughput and reproducibility, enabling a deeper and more efficient exploration of cellular biology. This is particularly vital as the industry increasingly demands comprehensive cellular profiling to understand disease mechanisms and develop targeted therapies.
“Single-cell multiomics is transforming research in crucial areas like oncology and immunology by revealing the complex layers of information within individual cells,” notes Ranga Partha, PhD, VP/GM of Global Marketing and Strategic Growth Areas, BD Biosciences. “Integrating robotics, particularly with our BD Rhapsody® HT Xpress System, which allows million-cell studies, empowers scientists with unprecedented speed, scale, and data integrity. This automation unlocks potentially life-changing insights with greater efficiency, pushing the boundaries of translational research and biopharmaceutical innovation.”
The core of the collaboration focuses on seamlessly integrating the BD Rhapsody™ System with the Opentrons Flex® platform. This integration will involve the development of verified protocols optimized for hands-free operation, simplifying complex single-cell multiomics workflows. A key component will be an automation-compatible module specifically designed for the BD Rhapsody™ System, automating crucial steps in next-generation sequencing library preparation and cell capture. This addresses the need for standardized and scalable workflows in a field heavily reliant on manual, error-prone procedures.
“This collaboration leverages BD’s deep expertise in single-cell multiomics and Opentrons’ open and adaptable automation ecosystem,” explains James Atwood, PhD, CEO of Opentrons Labworks. “By combining our respective hardware platforms, we are significantly reducing the barriers to entry for labs of all sizes to perform leading-edge single-cell sequencing at scale. This provides a more cost-effective solution for accelerating both basic and translational research breakthroughs.”
The collaboration reflects a growing trend in the life sciences industry toward automation and high-throughput technologies. The use of robotics in single-cell multiomics not only increases efficiency but also minimizes human error, leading to more reliable and reproducible results. This is particularly important for drug development, where accuracy and consistency are critical for identifying potential therapeutic targets and evaluating drug efficacy.
The companies plan to offer early access opportunities to select labs. Scientists interested in learning more about the partnership and the early access program can visit Opentrons (Booth 635) and BD (Booth 447) at the upcoming American Society of Human Genetics (ASHG) Annual Meeting in Boston, from October 14-18, 2025. Further details are also accessible at opentrons.com and bdbiosciences.com.
About BD
BD is a leading global medical technology company advancing the world of health by improving medical discovery, diagnostics, and the delivery of care. BD helps customers advance clinical therapy for patients and clinical process for health care providers. BD has a presence in virtually every country and partners with organizations around the world to address challenging global health issues. For more information on BD, please visit bd.com.
About Opentrons
Opentrons Labworks, Inc., is an innovator in entry-level lab automation, accelerating innovation in research and healthcare through its integrated lab platform. Opentrons Flex® offers open-source accessibility and compatibility with generative AI tools. Opentrons is used in labs at the top academic universities in the US and biopharmaceutical companies. Learn more at https://opentrons.com/.
“`
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/10563.html
